Market Spotlight: Thyroid Cancer
Market Spotlight: Thyroid Cancer
$1,318.00
This Market Spotlight report covers the Thyroid cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the thyroid cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence and five-year prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways:
- Datamonitor Healthcare estimates that in 2017, there were 559,800 incident cases of thyroid cancer worldwide, and expects that number to increase to 612,600 incident cases by 2026.
- In the same year, there were an estimated 2.0 million five-year prevalent cases of thyroid cancer worldwide, which is expected to increase to 2.2 million by 2026.
- The approved drugs in the thyroid cancer space focus on a wide variety of targets. These drugs are commonly administered via the oral route, with one product being available in an intramuscular formulation.
- There are only five industry-sponsored drugs in active clinical development for thyroid cancer, with three drugs in Phase II and two in Phase I.
- Therapies in early-to-mid-stage development for thyroid cancer focus on targets such as RET, carcinoembryonic antigen, immune system, tumor necrosis factor-alpha, and ErbB3/HER3. These therapies are administered via the oral, intravenous, and subcutaneous routes.
- The only high-impact upcoming event in the thyroid cancer space is topline Phase II trial results for GI-6207. The overall likelihood of approval of a Phase I solid tumors asset is 5.8%, and the average probability a drug advances from Phase III is 40.3%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- There have been 13 licensing and asset acquisition deals involving thyroid cancer drugs during 2014–19. The $1,550m exclusive global collaboration signed in November 2017 between Bayer and Loxo Oncology, for the development and commercialization of two novel oncology therapies selectively targeting genetic drivers of cancer, was the largest deal.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for thyroid cancer have been in the early and mid-phases of development, with 91% of trials in Phase I–II, and only 9% in Phase III–IV.
- The US has a substantial lead in the number of thyroid cancer clinical trials globally. France leads the major EU markets, while China has the top spot in Asia.
- Clinical trial activity in the thyroid cancer space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for thyroid cancer, with 28 trials.
- Novartis leads industry sponsors with the highest overall number of clinical trials for thyroid cancer, followed by Pfizer
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Thyroid cancer subtypes
10 TREATMENT
10 Surgery
10 Radioactive iodine (RAI) therapy
10 Thyroid hormone therapy
10 External beam radiation therapy
11 Targeted therapy
12 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
23 RECENT EVENTS AND ANALYST OPINION
23 BLU-667 for Thyroid Cancer (May 15, 2019)
24 Selumetinib for Thyroid Cancer (July 26, 2018)
26 LOXO-292 for Thyroid Cancer (June 2, 2018)
28 Lenvima for Thyroid Cancer (March 7, 2018)
29 Cabometyx / Cometriq for Thyroid Cancer (February 13, 2018)
32 KEY UPCOMING EVENTS
33 KEY REGULATORY EVENTS
33 Bayer Files Larotrectinib In EU As LOXO-292 Hurtles Towards The Market
34 PROBABILITY OF SUCCESS
35 LICENSING AND ASSET ACQUISITION DEALS
35 Lift-Off For Lilly In Cancer Genetics With Loxo Buy
37 PARENT PATENTS
38 REVENUE OPPORTUNITY
39 CLINICAL TRIAL LANDSCAPE
40 Sponsors by status
41 Sponsors by phase
43 BIBLIOGRAPHY
43 Prescription information
45 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of thyroid cancer, 2017–26
19 Figure 2: Overview of pipeline drugs for thyroid cancer in the US
19 Figure 3: Pipeline drugs for thyroid cancer, by company
20 Figure 4: Pipeline drugs for thyroid cancer, by drug type
20 Figure 5: Pipeline drugs for thyroid cancer, by classification
24 Figure 6: BLU-667 for Thyroid Cancer (May 15, 2019): Phase I – ARROW (NSCLC, Thyroid, Solids)
26 Figure 7: Selumetinib for Thyroid Cancer (July 26, 2018): Phase III – ASTRA
28 Figure 8: LOXO-292 for Thyroid Cancer (June 2, 2018): Phase I/II – LIBRETTO-001
31 Figure 9: Cabometyx / Cometriq for Thyroid Cancer (February 13, 2018): Phase II – RAI-DTC (Abramson)
32 Figure 10: Key upcoming events in thyroid cancer
34 Figure 11: Probability of success in the thyroid cancer pipeline
35 Figure 12: Licensing and asset acquisition deals in thyroid cancer, 2014-19
37 Figure 13: Parent patents in thyroid cancer
39 Figure 14: Clinical trials in thyroid cancer
39 Figure 15: Top 10 drugs for clinical trials in thyroid cancer
40 Figure 16: Top 10 companies for clinical trials in thyroid cancer
40 Figure 17: Trial locations in thyroid cancer
41 Figure 18: Thyroid cancer trials status
42 Figure 19: Thyroid cancer sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of thyroid cancer, 2017–26
15 Table 2: Five-year prevalent cases of thyroid cancer, 2017–26
17 Table 3: Marketed drugs for thyroid cancer
21 Table 4: Pipeline drugs for thyroid cancer in the US
23 Table 5: BLU-667 for Thyroid Cancer (May 15, 2019)
25 Table 6: Selumetinib for Thyroid Cancer (July 26, 2018)
26 Table 7: LOXO-292 for Thyroid Cancer (June 2, 2018)
29 Table 8: Lenvima for Thyroid Cancer (March 7, 2018)
30 Table 9: Cabometyx / Cometriq for Thyroid Cancer (February 13, 2018)
38 Table 10: Historical global sales, by drug ($m), 2014–18
38 Table 11: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the